866-997-4948(US-Canada Toll Free)

Abilify Analysis and Estimates from 2002 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 32 Pages


GlobalDatas pharmaceuticals report, Abilify Analysis and Estimates from 2002 to 2020 provides Abilify sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Abilify including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Abilify including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Abilify in each of the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Schizophrenia 4
2.2 Symptoms 4
2.3 Schizophrenia Market 4
2.4 Epidemiology 4
2.5 Etiology 5
2.5.1 Genetic Factors 5
2.5.2 Environmental Factors 5
2.5.3 Abnormal Brain Structure 6
2.6 GlobalData Report Guidance 6

3 Schizophrenia: Market Characterization 7
3.1 Schizophrenia Market 7
3.2 Schizophrenia Market Forecasts and CAGR 7
3.3 Drivers of Schizophrenia Therapeutics Market 8
3.3.1 Patent Expiry of Leading Marketed Drugs 8
3.3.2 Increasing Patient Pool 8
3.3.3 High Prescription Rates 8
3.3.4 Low Patient Compliance Rate 8
3.3.5 High Unmet Need 8

4 Classification of Schizophrenia 9
4.1 Age of Onset of Schizophrenia 9
4.1.1 Pediatric / Adolescent / Childhood Schizophrenia 9
4.1.2 Adult Schizophrenia 10
4.2 Associated Symptoms 10
4.2.1 Paranoid Schizophrenia 10
4.2.2 Disorganized Schizophrenia 10
4.2.3 Catatonic Schizophrenia 10
4.2.4 Residual Schizophrenia 10
4.2.5 Undifferentiated Disorder 10

5 Treatment for Schizophrenia 11
5.1 Crisis Resolution Teams (CRT) 11
5.2 Voluntary and Compulsory Detention 11
5.3 Antipsychotics 11
5.3.1 Typical Antipsychotics 11
5.3.2 Atypical Antipsychotics 12
5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis 12

6 Abilify 13
6.1 Introduction 13
6.2 Agreement between Otsuka and BMS 13
6.3 Mechanism of Action 13
6.4 Clinical Studies 13
6.4.1 Adult Patients 13
6.4.2 Pediatric Patients 15
6.5 Approval History of Abilify 15
6.6 Factors Affecting Sales of Abilify 16
6.6.1 Better Efficacy 16
6.6.2 Continued Dominance by Newer Agents in AntiPsychotic Market 16
6.6.3 Better Safety Profile 16
6.6.4 Agreement between Otsuka and BMS 16
6.6.5 Approval in Pediatric Patients 16
6.6.6 Patent Expiry of Abilify 16
6.7 Drug Evaluation 17
6.7.1 Drug Risk Benefit Score 17
6.7.2 Intensity of Competition 17
6.8 Sales Estimates 18
6.8.1 Target Patient Pool of Abilify 18
6.8.2 Dosing 18
6.8.3 Market Penetration 19
6.8.4 Annual Cost of Therapy 19
6.8.5 Sales Projections of Abilify 20

7 Schizophrenia Market: Appendix 29
7.1 Market Definitions 29
7.2 List of Abberiviations 29
7.3 Research Methodology 29
7.4 Drug Sales Estimates Model 31
7.5 Contact Us 32
7.6 Disclaimer 32
7.7 Sources 32

List of Table


Table 1: Results, CATIE Phase III Trial, 2008 14
Table 2: Abilify, Approval History 15
Table 3: Drug Risk Benefit Score 17
Table 4: Abilify, Dosage for Schizophrenia Patients 18
Table 5: Abilify, Annual Treatment Costs for Schizophrenia, Global, 2010 19
Table 6: Abilify, Schizophrenia, Global, Sales Estimates ($m), 20022020 20
Table 7: Abilify, Schizophrenia, The US, Sales Estimates ($m), 20022020 21
Table 8: Abilify, Schizophrenia, The UK, Sales Estimates ($m), 20042020 22
Table 9: Abilify, Schizophrenia, France, Sales Estimates ($m), 20042020 23
Table 10: Abilify, Schizophrenia, Germany, Sales Estimates ($m), 20042020 24
Table 11: Abilify, Schizophrenia, Italy, Sales Estimates ($m), 20042020 25
Table 12: Abilify, Schizophrenia, Spain, Sales Estimates ($m), 20042020 26
Table 13: Abilify, Schizophrenia, Japan, Sales Estimates ($m), 20062020 27

List of Chart


Figure 1: Risk of Developing Schizophrenia 5
Figure 2: Environmental Factors in the Development of Schizophrenia 6
Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 20102020 7
Figure 4: Classification of Schizophrenia based on the Age of Disease Onset 9
Figure 5: Drug Model Diagram of Abilify 18
Figure 6: Abilify, Schizophrenia, Global, Sales Estimates ($m), 20022020 20
Figure 7: Abilify, Schizophrenia, The US, Sales Estimates ($m), 20022020 21
Figure 8: Abilify, Schizophrenia, The UK, Sales Estimates ($m), 20042020 22
Figure 9: Abilify, Schizophrenia, France, Sales Estimates ($m), 20042020 23
Figure 10: Abilify, Schizophrenia, Germany, Sales Estimates ($m), 20042020 24
Figure 11: Abilify, Schizophrenia, Italy, Sales Estimates ($m), 20042020 25
Figure 12: Abilify, Schizophrenia, Spain, Sales Estimates ($m), 20042020 26
Figure 13: Abilify, Schizophrenia, Japan, Sales Estimates ($m), 20062020 27
Figure 14: Abilify, Schizophrenia, Global, Sales Distribution in Major Countries (%), 2014 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *